变应性鼻炎特异性免疫治疗全身不良反应观察及危险因素分析
该回顾性研究分析了102例接受皮下特异性免疫治疗(SCIT)的变应性鼻炎患者,共1608次注射中发生12例21次全身不良反应,以全身性荨麻疹、血管性水肿和Ⅰ级反应为主,并探讨了可能的危险因素。
要点
- SCIT全身不良反应以全身性荨麻疹、血管性水肿和Ⅰ级反应为主。
- 不良反应多发生于剂量递增的初始治疗阶段及变应原绝对量较大时。
- 明显局部不良反应是最常见的可能危险因素(17/21)。
核心结论
- SCIT诱发的全身不良反应主要为全身性荨麻疹、血管性水肿和Ⅰ级全身不良反应。
- 全身不良反应易发生于注射剂量和浓度逐渐增加的初始治疗阶段及变应原绝对量较大时。
研究设计与样本
- 回顾性研究,纳入2015年1月至2017年3月重庆医科大学附属第一医院耳鼻咽喉科行SCIT的AR患者102例,共1608次注射。
主要发现
- 12例患者发生21次全身不良反应,包括全身性荨麻疹、血管性水肿和Ⅰ级全身不良反应,另含3例Ⅳ级不良反应。
- 全身不良反应多见于20~40岁患者,易发生于5~6月份。
- 可能危险因素中明显局部不良反应最多见(17/21),其次为注射间隔时间延长(9/21)、近期接触大量变应原(7/21)和皮肤点刺结果强阳性(7/21)。
临床怎么用
- 在SCIT初始剂量递增阶段及注射变应原绝对量较大时应加强监测。
- 关注20~40岁患者及5~6月份的不良反应风险。
- 出现明显局部不良反应、注射间隔延长、近期大量变应原接触或皮肤点刺强阳性时需警惕全身不良反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the systemic adverse effects of specific subcutaneous immunotherapy (SCIT) in patients with allergic rhinitis (AR) and explore the possible risk factors. Methods: A retrospective study was conducted on AR patients who underwent SCIT from January 2014 to January 2017 in Department of Otorhinolaryngology, the First Affiliated Hospital of Chongqing Medical University. For patients with adverse reactions, the detailed medical history during treatment was reviewed. Results: A total of 1608 injections were performed on 102 patients, there were 12 cases / 21 times systemic adverse events, including systemic urticaria, angioedema and Grade Ⅰ systemic adverse reactions. There were 3 cases of grade Ⅳ adverse reactions. Systemic adverse reaction was prone to an initial treatment phase where the dose and concentration of the injection were increasing. Meanwhile, it was more common in young patients aged 20-40 years old and easy to occur in May and June. About the possible risk factors, the most common one was obvious local adverse reactions (17/21), followed by prolonged injection interval (9/21), the recent exposure to a large number of allergens (7/21) and strong positive skin prick results (7/21). Conclusions: The systemic adverse effects, which were induced by SCIT, mainly included systemic urticaria, angioedema and Grade Ⅰ systemic adverse reactions. Systemic adverse reaction was prone to an initial treatment phase where the dose and concentration of the injection were increasing. 目的: 观察变应性鼻炎(allergic rhinitis,AR)患者特异性皮下免疫治疗(subcutaneous immunotherapy,SCIT)的全身不良反应,探寻可能的危险因素。 方法: 对2015年1月至2017年3月在重庆医科大学附属第一医院耳鼻咽喉科行SCIT的AR患者进行回顾性调查,对发生不良反应的患者分析其治疗过程中的详细病史资料。 结果: 在对102例AR患者的1 608次SCIT注射中,共有12例患者发生21次全身不良反应,以全身性荨麻疹、血管性水肿和Ⅰ级全身不良反应为主,另包含3例Ⅳ级不良反应。全身不良反应多发生于注射剂量和浓度逐渐增加的初始治疗阶段及注射的变应原绝对量较大时;多见于20~40岁患者;易发生于5~6月份。在可能诱发全身不良反应的危险因素中,以明显局部不良反应最多见(17/21),其次为注射间隔时间延长(9/21)、近期接触大量变应原(7/21)和皮肤点刺结果强阳性(7/21)。 结论: SCIT诱发的全身不良反应,主要表现为全身性荨麻疹和血管性水肿,以Ⅰ级全身不良反应为主;更易发生于注射剂量和浓度逐渐增加的初始治疗阶段,及注射的变应原绝对量较大时。.
引用
- Shen Y, Hong SL, Zhang M, et al. [Observation of systemic adverse reactions by specific immunotherapy and analysis of risk factors in allergic rhinitis]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017. PMID: 29141287. doi:10.3760/cma.j.issn.1673-0860.2017.11.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。